17,261 trials
Type 1 Diabetes Mellitus · New-onset Type 1 Diabetes Mellitus · T1DM
Primary: Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC) in Pediatric Participants — -0.337; -0.391 pmol/mL — p=0.277
Amyotrophic Lateral Sclerosis
Primary: Number of Participants With Potentially Clinically Significant Hematology Results — 5; 2; 3; 4 Participants
Cutaneous T-Cell Lymphoma
Primary: Overall Response Rate of Participants Using the Modified Severity-Weighted Assessment Tool (mSWAT) — 16.7; 20.3; 18.5 percentage
Schizophrenia
Primary: Prepulse Inhibition (PPI) — 22.629; 41.162; 50.626; 50.626 % inhibition of startle
Myelodysplastic Syndrome · Iron Overload
Primary: Number of Participants Reporting Adverse Events — 171 Participants
Asthma
Primary: FEV1 Area Under the Curve Between 0 and 12 h [AUC(0-12h)], Normalized by Time -- Change From Baseline to Post Dose Day 14 — 0.174; 0.221; 0.197; 0.231 Litres — p=<0.001
Alzheimer's Disease · Psychosis · Agitation
Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53
Advanced Solid Tumors · Acute Myeloid Leukemia
Primary: Number of Participants With Adverse Events — 2; 3; 3; 1 Participants
Plaque Psoriasis · Psoriasis · Skin Diseases
Primary: Percentage of Subjects Achieving a Minimum 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI-75) at End-of-treatment (EOT) — 11.8; 22.0; 7.8 %…
Reduction in Severity of Skin Scarring
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 8; 0 Participants
Non-Neoplastic Hematologic and Lymphocytic Disorder
Primary: Preliminary Efficacy — 83; 10 Participants
Melanoma
Primary: Comparison of Immune Responses of Vaccine+R848 to Vaccine Alone
Nicotine Dependence
Primary: Biochemically-confirmed 30-day Continuous Smoking Abstinence — 5; 3; 18; 5 Participants
Thrombotic Thrombocytopenic Purpura
Primary: Incidence of the Composite Primary Outcome of Exacerbation or Refractory TTP — 2; 0 Participants
Neonatal Anemia
Primary: Number of Discrete Biotinylated RBC Densities (up to 5 Discrete Densities) That Can be Accurately Measured by Flow Cytometry, i.e., Without Overlap. — 5; 5 flow…